THC could be a chemotherapeutic agent for treating stomach cancer

Cannabinoids, such as THC, which activate the CB1 and CB2 cannabinoid receptors are more effective against stomach cancer than the main chemotherapy treatment. Using marijuana protects us from so many cancers and other illnesses, aren't you mad that it's still illegal? Anticancer Res. 2013 Jun;33(6):2541-7.

Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells.

Xian XS, Park H, Choi MG, Park JM.

Source

Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 505, Banpo-Dong, Seocho-Gu, Seoul, 137-070, Korea. parkjerry@catholic.ac.kr.

Abstract

Fluorouracil is the main chemotherapeutic drug used for gastrointestinal cancers, which suffers the important problem of treatment resistance. There is little information whether cannabinoid agonists can be used as an alternative drug for fluorouracil-resistant gastric cancer cells. In this study, we investigated the effects of a cannabinoid agonist, WIN-55,212-2, on 5-fluorouracil (5-FU)-resistant human gastric cancer cells, to examine whether the cannabinoid agonist may be an alternative therapy. Survival of the 5-FU-resistant gastric cancer cell line, SNU-620-5FU/1000, was not significantly reduced even by a high dose of 5-FU treatment. However, WIN-55,212-2 inhibited the proliferation of SNU-620-5FU/1000 and enhanced their apoptosis, as indicated by an increase of apoptotic cell proportion, activated caspase-3 and Poly (ADP-ribose) polymerase cleavage. Furthermore, WIN-55,212-2 reduced phospho-extracellular-signal-regulated kinases (ERK) 1/2, phospho-Akt (protein kinase B), B-cell lymphoma-2 (BCL2) and BCL2-associated X (BAX) protein expression in 5-FU-resistant gastric cancer cells. These results indicate that a cannabinoid agonist may, indeed, be an alternative chemotherapeutic agent for 5-FU-resistant gastric cancer.

KEYWORDS:

Gastric cancer, apoptosis, cannabinoids, drug resistance, fluorouracil

via Cannabinoid Receptor Agonist as an Alternativ... [Anticancer Res. 2013] - PubMed - NCBI.